Australia has a new policy that can allow conditional approval at an early point in a trial if it wants to, and based on the Alzheimer 2-73 Trial, Anavex with success is now in position to have an early conditional approval in Australia.
I look forward to a coupling of RWE/RWD-Early conditional approval for CNS-AD from Australian regulatory body(according to regulatory requirements) w/ USA adopting and applying controlled use of A2-73 under appropriate U.S.A.Right To Try (RTT) guidance.
This cannot happen soon enough for those of us w/close family and extended family members who are still full of life but fading before our eyes b/c of dementia-AD.